Target intelligence / Profile preview

Cytochrome P450 family 2 subfamily E member 1 (CYP2E1)

Target
CYP2E1
Molecular classification
Enzyme, Monooxygenase, Microsomal cytochrome P450
01

Overview

Cytochrome P450 family 2 subfamily E member 1 (CYP2E1) is a membrane-bound monooxygenase enzyme found primarily in the liver, where it metabolizes small molecule substrates including ethanol, anesthetics, and chemical carcinogens. It plays crucial roles in drug metabolism, detoxification, and the synthesis of endogenous molecules; however, it can also generate toxic or carcinogenic metabolites. Its expression is highly inducible by ethanol, fasting, diabetes, and other states, and its activity is central to both normal physiology (e.g., gluconeogenesis and fatty acid metabolism) and pathophysiological conditions such as alcoholic liver disease and cancer risk. CYP2E1's ability to metabolize many low molecular weight compounds makes it a key therapeutic target and a source of safety concern when the enzyme is induced or dysfunctional.

Other names
CYP2E1Cytochrome P450 2E1Cytochrome P450, Subfamily IIE (Ethanol-Inducible), Polypeptide 1Cytochrome P450, Family 2, Subfamily E, Polypeptide 1CYP2ECytochrome P450-JEC 1.14.14.14-Nitrophenol 2-Hydroxylase
02

Mechanism of action

Oxidation and hydroxylation of substrates. Bioactivation of procarcinogens. Generation of toxic metabolites. Catalysis of monooxygenase reactions: RH + O₂ + 2H⁺ + 2e⁻ → ROH + H₂O

03

Biological functions

Drug metabolismMetabolism of xenobioticsEther and ethanol oxidationSynthesis of cholesterol, steroids, and lipidsGluconeogenesisFatty acid metabolismGeneration of reactive oxygen species (ROS) under some conditions
04

Disease associations

Alcoholic liver disease (including cirrhosis)DiabetesObesityLiver cancerToxicity from xenobiotics (including acetaminophen overdose)Cancer (activation of procarcinogens such as nitrosamines)Other conditions involving hepatic or metabolic dysfunction
05

Safety considerations

Hepatotoxicity from enhanced drug or toxin metabolism (e.g., acetaminophen overdose)Increased carcinogenic risk from activation of nitrosaminesHigh variability of enzyme concentration among humans (affecting drug efficacy and toxicity)Increased production of toxic metabolites with alcohol induction or certain disease states
06

Interacting drugs

Acetaminophen (paracetamol)

7 more in the full profile.

07

Biomarkers

4-nitrophenol metabolite ratio (as a marker of CYP2E1 activity)CYP2E1 protein abundance (for patient-specific pharmacokinetics and toxicity risk)

Beyond the preview

Go deeper on Cytochrome P450 family 2 subfamily E member 1 (CYP2E1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cytochrome P450 family 2 subfamily E member 1 (CYP2E1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call